Evaluación de la calidad de vida y la presencia de síntomas de depresión y ansiedad en pacientes con degeneración macular asociada a la edad neovascular

  1. J.I. Fernández-Vigo 123
  2. B. Burgos Blasco 13
  3. C. Calvo González 13
  4. M.J. Escobar Moreno 13
  5. H. Shi 13
  6. M. Jiménez Santos 13
  7. A. Valverde Megías 13
  8. J. Reche Frutos 13
  9. L. López Guajardo 13
  10. J. Donate López 13
  1. 1 Hospital Clínico San Carlos de Madrid
    info

    Hospital Clínico San Carlos de Madrid

    Madrid, España

    ROR https://ror.org/04d0ybj29

  2. 2 Centro Internacional de Oftalmología Avanzada, Madrid, España
  3. 3 Instituto de Investigación Sanitaria del Hospital Clínico San Carlos
    info

    Instituto de Investigación Sanitaria del Hospital Clínico San Carlos

    Madrid, España

    ROR https://ror.org/014v12a39

Show affiliations +
Journal:
Archivos de la Sociedad Española de Oftalmologia

ISSN: 0365-6691

Year of publication: 2021

Volume: 96

Issue: 9

Pages: 470-475

Type: Article

DOI: 10.1016/J.OFTAL.2020.11.010 DIALNET GOOGLE SCHOLAR

More publications in: Archivos de la Sociedad Española de Oftalmologia

Abstract

Purpose To assess the vision-related quality of life and the depression and anxiety rates in patients with neovascular Age-Related Macular Degeneration (nAMD). Methods A cross-sectional study of patients with nAMD treated with intravitreal injections was performed. The patients completed two validated questionnaires: the Visual Functioning Questionnaire (VFQ-25, score from 0 to 100), and the Hospital Anxiety and Depression Scale (HADS) questionnaire. Age, gender and visual acuity (VA) in the Early Treatment Diabetic Retinopathy Study (ETDRS) scale was registered. Results Fifty-five patients with nAMD participated with a mean age of 80.9 ± 6.6 years-old (range 67 to 93) and a mean VA in the best eye of 73.5 ± 12.7 letters (range 44 to 95). The global VFQ-25 mean score was 57.4 ± 21.9 being 38.9 ± 13.2 for the general vision and 42.0 ± 19.5 for the general health. VA in the best eye was associated with the global score of the VFQ-25 scale (R = .608; P < .001), but no correlation was observed with general health (P = .936). In the HADS scale, 26.9% and 25.5% of patients had symptoms of depression and anxiety respectively. A negative correlation was found between the HADS and VFQ-25 scales for the general vision score (R = –0.438). Conclusions This study elucidates the impact of vision impairment and the visual functioning in nAMD, describing an important rate of depression and anxiety symptoms.

Data source: Dialnet